Article
Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia.
Blood advances - 11 Jan 2022
Wakita Satoshi, Sakaguchi Masahiro, Oh Iekuni, Kako Shinichi, Toya Takashi, Najima Yuho, Doki Noriko, Kanda Junya, Kuroda Junya, Mori Shinichiro, Satake Atsushi, Usuki Kensuke, Ueki Toshimitsu, Uoshima Nobuhiko, Kobayashi Yutaka, Kawata Eri, Tajika Kenji, Nagao Yuhei, Shono Katsuhiro, Shibusawa Motoharu, Tadokoro Jiro, Kayamori Kensuke, Hagihara Masao, Uchiyama Hitoji, Uchida Naoyuki, Kubota Yasushi, Kimura Shinya, Nagoshi Hisao, Ichinohe Tatsuo, Kurosawa Saiko, Motomura Sayuri, Hashimoto Akiko, Muto Hideharu, Sato Eriko, Ogata Masao, Mitsuhashi Kenjiro, Ando Jun, Marumo Atsushi, Omori Ikuko, Fujiwara Yusuke, Terada Kazuki, Yui Shunsuke, Arai Kunihito, Kitano Tomoaki, Miyata Miho, Kurosawa Akiyo, Mizoguchi Ayumi, Komatsu Norio, Fukuda Takahiro, Ohashi Kazuteru, Kanda Yoshinobu, Inokuchi Koiti, Yamaguchi Hiroki
Abstract excerpt
Mutations of CCAAT/enhancer-binding protein alpha (CEBPAmu) are found in 10% to 15% of de novo acute myeloid leukemia (AML) cases. Double-mutated CEBPA (CEBPAdm) is associated with a favorable prognosis; however, single-mutated CEBPA (CEBPAsm) does not seem to improve prognosis. We investigated CEBPAmu for prognosis in 1028 patients with AML, registered in the Multi-center Collaborative Program for Gene...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.